12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BOL-303259-X: Completed Phase IIb enrollment

Bausch + Lomb completed enrollment of about 400 patients in a single-blind, dose-ranging, international Phase IIb trial comparing once-daily BOL-303259-X vs. Xalatan latanoprost for 28 days. NicOx granted Bausch +...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >